It is structurally related to a naturally occurring protein fragment identified in human gastric juice, often referred to in the scientific literature as Body Protection Compound (BPC)
It remains an investigational medicinal product (IMP), meaning it is only available within the context of authorised clinical trials
You can join if you are eligible through your employer, health plan or healthcare provider and meet the program criteria
According to clinical trials, nausea affects approximately 43% of patients, diarrhoea 22%, vomiting 15%, and constipation 24%
Yes low fiber, dysbiosis, or inflammation reduces SCFAs, weakening GLP-1 output and increasing hunger and cravings
Metabolic shifts toward fatty-acid usage and increased thermogenesis are associated with impaired adipogenesis in mice expressing human APOE4